# Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-

Source: https://onco.cc/trials/nct06819007/  
OnCo record `nct06819007` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Trastuzumab deruxtecan, Bevacizumab in ovarian cancer, run by Daiichi Sankyo, now recruiting.

## Summary

Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01) is a phase 3 interventional study registered as NCT06819007 by Daiichi Sankyo, with 582 participants planned, started 2025-03-19 and due to reach its primary completion in 2028-11-01. Interventions recorded: Trastuzumab Deruxtecan, Bevacizumab. Conditions listed: Ovarian Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06819007
- Phase: 3
- Setting: A Phase 3, Open-label, Multicenter, Randomized Trial of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy as First-line Maintenance Therapy in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01/ENGOT-ov89/GEICO144- O/GOG-3112/APGOT-OV13)
- Sponsor: Daiichi Sankyo
- Enrolled: 582

## Sources

- ClinicalTrials.gov NCT06819007: https://clinicaltrials.gov/study/NCT06819007

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Trastuzumab deruxtecan](https://onco.cc/drugs/trastuzumab-deruxtecan/)
- companies: [Daiichi Sankyo](https://onco.cc/companies/daiichi-sankyo/)

---
JSON: https://onco.cc/api/v1/entities/nct06819007.json